HALO - Halozyme Therapeutics Inc Stock Price, Fair Value and News

39.12USD+0.15 (+0.38%)Market Closed

Market Summary

USD39.12+0.15

Market Closed

0.38%

HALO Alerts

1 major insider sales recently.

HALO Stock Price

View Fullscreen

HALO RSI Chart

HALO Valuation

Market Cap

5.0B

Price/Earnings (Trailing)

17.62

Price/Sales (Trailing)

5.98

EV/EBITDA

16.77

Price/Free Cashflow

13.29

HALO Price/Sales (Trailing)

HALO Profitability

EBT Margin

42.01%

Return on Equity

336%

Return on Assets

16.25%

Free Cashflow Yield

7.52%

HALO Fundamentals

HALO Revenue

Revenue (TTM)

829.3M

Rev. Growth (Yr)

26.75%

Rev. Growth (Qtr)

6.48%

HALO Earnings

Earnings (TTM)

281.6M

Earnings Growth (Yr)

47.98%

Earnings Growth (Qtr)

4.34%

Breaking Down HALO Revenue

Last 7 days

2.9%

Last 30 days

-3.2%

Last 90 days

13.4%

Trailing 12 Months

16.5%

How does HALO drawdown profile look like?

HALO Financial Health

Current Ratio

6.64

Debt/Equity

17.89

Debt/Cashflow

0.26

HALO Investor Care

Buy Backs (1Y)

6.31%

Diluted EPS (TTM)

2.11

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	705.0M	773.7M	780.7M	829.3M
2022	471.6M	487.5M	580.6M	660.1M
2021	331.3M	412.5M	463.0M	443.3M
2020	164.4M	180.5M	199.6M	267.6M
2019	177.9M	181.9M	202.6M	196.0M
2018	317.9M	319.4M	281.2M	151.9M
2017	133.8M	134.2M	166.1M	316.6M
2016	146.7M	146.7M	146.7M	146.7M
2015	105.9M	120.8M	138.1M	146.7M
2014	54.9M	58.9M	57.5M	75.3M
2013	46.7M	53.4M	64.1M	54.8M
2012	56.0M	40.6M	22.9M	42.3M
2011	17.7M	37.7M	57.2M	56.1M
2010	0	13.7M	13.6M	13.6M
2009	0	0	0	13.7M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Halozyme Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 17, 2024	labarre michael j.	acquired	81,100	8.11	10,000	svp, chief technical officer
Apr 17, 2024	labarre michael j.	sold	-384,890	38.489	-10,000	svp, chief technical officer
Apr 16, 2024	labarre michael j.	acquired	81,100	8.11	10,000	svp, chief technical officer
Apr 16, 2024	labarre michael j.	sold	-383,500	38.35	-10,000	svp, chief technical officer
Mar 26, 2024	labarre michael j.	acquired	130,160	11.2033	11,618	svp, chief technical officer
Mar 13, 2024	labarre michael j.	sold	-422,730	42.273	-10,000	svp, chief technical officer
Mar 13, 2024	labarre michael j.	acquired	106,638	10.6638	10,000	svp, chief technical officer
Mar 12, 2024	labarre michael j.	acquired	120,700	12.07	10,000	svp, chief technical officer
Mar 12, 2024	labarre michael j.	sold	-416,370	41.637	-10,000	svp, chief technical officer
Feb 28, 2024	labarre michael j.	acquired	60,589	8.11	7,471	svp, chief technical officer

Which funds bought or sold HALO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	REGIONS FINANCIAL CORP	reduced	-2.48	15,699	229,883	-%
Apr 23, 2024	Arbor Investment Advisors, LLC	unchanged	-	66,774	730,206	0.11%
Apr 23, 2024	NATIONS FINANCIAL GROUP INC, /IA/ /ADV	added	48.13	148,470	383,979	0.03%
Apr 23, 2024	NEW MEXICO EDUCATIONAL RETIREMENT BOARD	unchanged	-	103,000	1,123,000	0.04%
Apr 23, 2024	Global Retirement Partners, LLC	reduced	-7.89	85.00	2,848	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-16.43	-245,000	2,814,000	0.02%
Apr 23, 2024	FIFTH THIRD BANCORP	reduced	-0.23	39,792	445,243	-%
Apr 23, 2024	Louisiana State Employees Retirement System	added	2.43	174,624	1,545,840	0.03%
Apr 23, 2024	Livforsakringsbolaget Skandia, Omsesidigt	unchanged	-	19,451	215,339	0.02%
Apr 22, 2024	MetLife Investment Management, LLC	reduced	-0.76	-214,658	5,178,720	0.04%

Are Funds Buying or Selling HALO?

Are funds buying HALO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own HALO

No. of Funds

HALO Alerts

1 major insider sales recently.

Unveiling Halozyme Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	10.04%	13,259,514	SC 13G/A
Feb 12, 2024	artisan partners limited partnership	5.1%	6,689,058	SC 13G/A
Feb 01, 2024	invesco ltd.	2.1%	2,816,427	SC 13G/A
Jan 23, 2024	blackrock inc.	14.1%	18,629,818	SC 13G/A
Jun 09, 2023	vanguard group inc	10.27%	13,528,630	SC 13G/A
Feb 10, 2023	invesco ltd.	5.2%	7,036,951	SC 13G
Feb 10, 2023	blackrock inc.	14.2%	19,196,061	SC 13G/A
Feb 10, 2023	artisan partners limited partnership	5.3%	7,140,953	SC 13G/A
Feb 09, 2023	vanguard group inc	9.84%	13,303,847	SC 13G/A
Jan 26, 2023	blackrock inc.	13.6%	18,214,071	SC 13G/A

Recent SEC filings of Halozyme Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 17, 2024	144	Notice of Insider Sale Intent
Apr 17, 2024	4	Insider Trading
Apr 16, 2024	144	Notice of Insider Sale Intent
Mar 26, 2024	4	Insider Trading
Mar 15, 2024	ARS	ARS
Mar 15, 2024	DEF 14A	DEF 14A
Mar 15, 2024	DEFA14A	DEFA14A
Mar 13, 2024	4	Insider Trading
Mar 13, 2024	144	Notice of Insider Sale Intent
Mar 12, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Halozyme Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	-1.39%	-19.31%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.44%	-28.86%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	5.41%	-4.57%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.99%	-29.65%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-10.10%	-42.90%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-14.83%	70.74%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-7.99%	-0.08%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.49%	-30.64%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-7.01%	-17.50%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.67%	-6.03%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-13.72%	-45.61%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	-0.25%	294.45%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-18.06%	3.25%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	70.91%	57.98%	-0.24	2.14	-13.45%	66.37%

Halozyme Therapeutics Inc News

Latest updates

Halozyme Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	6.5%	230	216	221	162	181	209	152	117	102	116	136	89.00	122	65.00	55.00	25.00	54.00	46.00	39.00	57.00	60.00
Costs and Expenses	1.0%	129	128	127	108	107	126	118	42.00	45.00	40.00	43.00	38.00	44.00	25.00	26.00	29.00	86.00	71.00	53.00	54.00	60.00
S&GA Expenses	6.6%	38.00	35.00	39.00	37.00	38.00	34.00	57.00	14.00	14.00	13.00	12.00	11.00	10.00	12.00	11.00	13.00	24.00	18.00	17.00	18.00	18.00
R&D Expenses	23.2%	21.00	17.00	20.00	18.00	23.00	17.00	15.00	12.00	10.00	8.00	8.00	9.00	7.00	8.00	9.00	10.00	45.00	30.00	34.00	31.00	37.00
EBITDA Margin	2.7%	0.46*	0.44*	0.41*	0.36*	0.41*	0.43*	0.50*	0.65*	0.58*	0.61*	0.60*	0.55*	-	-	-	-	-	-	-	-	-
Interest Expenses	15.9%	5.00	5.00	4.00	5.00	5.00	8.00	3.00	2.00	2.00	2.00	2.00	2.00	5.00	5.00	5.00	5.00	4.00	2.00	3.00	3.00	4.00
Income Taxes	-20.6%	16.00	20.00	18.00	13.00	13.00	12.00	7.00	14.00	-11.96	-142	0.00	0.00	0.00	0.00	0.00	0.00	-0.06	0.00	0.00	0.00	0.00
Earnings Before Taxes	-0.6%	101	102	93.00	52.00	71.00	74.00	30.00	74.00	55.00	74.00	92.00	28.00	73.00	36.00	26.00	-6.09	-34.46	-25.00	-14.61	2.00	-1.81
EBT Margin	3.1%	0.42*	0.41*	0.37*	0.32*	0.38*	0.40*	0.48*	0.63*	0.56*	0.58*	0.56*	0.49*	-	-	-	-	-	-	-	-	-
Net Income	4.3%	85.00	82.00	75.00	40.00	58.00	62.00	23.00	60.00	67.00	217	91.00	28.00	73.00	36.00	26.00	-6.10	-34.40	-25.01	-14.62	2.00	-2.13
Net Income Margin	4.4%	0.34*	0.33*	0.30*	0.26*	0.31*	0.36*	0.75*	0.92*	0.91*	0.88*	0.55*	0.49*	-	-	-	-	-	-	-	-	-
Free Cashflow	-22.9%	100	129	68.00	76.00	80.00	69.00	39.00	47.00	82.00	121	36.00	58.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-8.4%	1,733	1,893	1,810	1,699	1,842	1,865	1,781	1,162	1,104	1,185	1,026	967	580	524	527	492	566	370	418	429	440
Current Assets	-15.1%	746	879	766	615	739	653	542	989	926	1,017	1,000	942	555	499	500	468	543	342	392	409	428
Cash Equivalents	-56.8%	118	274	221	96.00	234	148	91.00	118	119	492	447	500	148	66.00	134	105	121	60.00	68.00	61.00	58.00
Inventory	-1.0%	128	129	132	108	100	103	98.00	48.00	54.00	56.00	59.00	58.00	61.00	58.00	48.00	41.00	29.00	36.00	44.00	31.00	23.00
Net PPE	-	-	-	-	-	-	-	-	-	-	-	10.00	10.00	11.00	10.00	11.00	12.00	11.00	15.00	15.00	15.00	7.00
Goodwill	0%	417	417	417	416	409	199	199	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	0.4%	1,649	1,643	1,659	1,634	1,672	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Current Liabilities	-2.3%	112	115	116	92.00	131	109	200	112	117	113	114	107	421	27.00	26.00	42.00	86.00	108	135	139	149
Long Term Debt	0.1%	1,499	1,498	1,496	1,494	1,493	1,491	1,147	788	787	786	786	785	-	394	390	387	383	9.00	14.00	19.00	35.00
LT Debt, Current	-	-	-	-	-	13.00	13.00	99.00	90.00	89.00	89.00	89.00	89.00	397	-	-	3.00	20.00	55.00	71.00	87.00	92.00
LT Debt, Non Current	0.1%	1,499	1,498	1,496	1,494	1,493	1,491	-	-	787	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-66.4%	84.00	249	151	66.00	170	97.00	293	260	197	282	120	68.00	151	99.00	106	58.00	92.00	245	260	260	249
Retained Earnings	-59.3%	91.00	222	140	66.00	143	86.00	24.00	1.00	-58.91	-125	-342	-433	-474	-547	-583	-609	-603	-569	-544	-529	-531
Additional Paid-In Capital	-90.6%	2.00	26.00	12.00	-	27.00	13.00	271	262	256	407	462	501	625	646	688	668	695	814	804	789	780
Shares Outstanding	-4.0%	127	132	132	132	135	137	138	138	141	142	140	138	-	-	-	-	-	-	-	-	-
Float	-	-	-	3,500	-	-	-	5,100	-	-	-	5,600	-	-	-	2,900	-	-	-	2,500	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-22.7%	102,354	132,411	66,842	86,964	82,453	69,635	40,225	47,797	82,516	121,739	36,889	58,296	50,920	6,084	3,294	-4,844	-26,625	-29,588	-24,786	-4,424	10,462
Share Based Compensation	3.2%	9,664	9,368	9,622	7,966	7,223	6,797	5,635	4,742	5,126	5,399	5,372	4,923	4,196	4,220	4,257	4,531	7,229	8,239	9,833	9,475	9,012
Cashflow From Investing	90.1%	-8,291	-83,450	54,994	-60,162	-1,746	-1,008	-434,946	-49,305	-299,469	-16,954	-44,616	-45,250	58,441	-30,095	11,899	38,109	-122,818	40,999	47,457	28,813	10,809
Cashflow From Financing	-6194.1%	-249,920	4,101	2,446	-164,614	6,329	-12,400	367,818	624	-156,011	-60,068	-44,757	338,701	-27,399	-43,854	13,593	-48,624	210,420	-19,250	-16,225	-21,730	-18,354
Buy Backs	-	252,300	-	-	150,083	1.00	200,001	-	-	160,321	64,716	48,842	76,179	38,896	58,902	1,996	51,574	-	-	-	-	-

HALO Income Statement

2023-12-31

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues
Total revenues	$ 829,253	$ 660,116	$ 443,310
Operating expenses
Cost of sales	192,361	139,304	81,413
Amortization of intangible assets	73,773	43,148	0
Research and development	76,363	66,607	35,672
Selling, general and administrative	149,182	143,526	50,323
Total operating expenses	491,679	392,585	167,408
Operating income	337,574	267,531	275,902
Other income (expense)
Investment and other income, net	16,317	1,046	1,102
Induced conversion expense related to convertible notes	0	(2,712)	(20,960)
Contingent liability fair value measurement gain	13,200	0	0
Interest expense	(18,762)	(16,947)	(7,526)
Net income before income taxes	348,329	248,918	248,518
Income tax expense (benefit)	66,735	46,789	(154,192)
Net income	$ 281,594	$ 202,129	$ 402,710
Earnings per share
Basic (usd per share)	$ 2.13	$ 1.48	$ 2.86
Diluted (usd per share)	$ 2.10	$ 1.44	$ 2.74
Weighted average common shares outstanding
Basic (in shares)	131,927	136,844	140,646
Diluted (shares)	134,197	140,608	146,796
Royalties
Revenues
Total revenues	$ 447,865	$ 360,475	$ 203,900
Product sales, net
Revenues
Total revenues	300,854	191,030	104,224
Revenues under collaborative agreements
Revenues
Total revenues	$ 80,534	$ 108,611	$ 135,186

HALO Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 118,370,000	$ 234,195,000
Marketable securities, available-for-sale	217,630,000	128,599,000
Accounts receivable, net and other contract assets	234,210,000	231,072,000
Inventories, net	127,601,000	100,123,000
Prepaid expenses and other current assets	48,613,000	45,024,000
Total current assets	746,424,000	739,013,000
Property and equipment, net	74,944,000	75,570,000
Prepaid expenses and other assets	17,816,000	26,301,000
Goodwill	416,821,000	409,049,000
Intangible assets, net	472,879,000	546,652,000
Deferred tax assets, net	4,386,000	44,426,000
Restricted cash	0	500,000
Total assets	1,733,270,000	1,841,511,000
Current liabilities
Accounts payable	11,816,000	17,693,000
Accrued expenses	100,678,000	99,762,000
Current portion of long-term debt, net	0	13,334,000
Total current liabilities	112,494,000	130,789,000
Long-term debt, net	1,499,248,000	1,492,766,000
Other long-term liabilities	37,720,000	32,686,000
Contingent liability	0	15,472,000
Total liabilities	1,649,462,000	1,671,713,000
Commitments and contingencies (Note 12)
Stockholders’ equity
Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding	0	0
Common stock - $0.001 par value; 300,000 shares authorized; 126,770 and 135,154 shares issued and outstanding as of December 31, 2023 and 2022, respectively	127,000	135,000
Additional paid-in capital	2,409,000	27,368,000
Accumulated other comprehensive loss	(9,278,000)	(922,000)
Retained earnings	90,550,000	143,217,000
Total stockholders’ equity	83,808,000	169,798,000
Total liabilities and stockholders’ equity	$ 1,733,270,000	$ 1,841,511,000

About Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

CEO	Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
WEBSITE	https://halozyme.com
INDUSTRY	Biotechnology
EMPLOYEES	393

Halozyme Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Halozyme Therapeutics Inc? What does HALO stand for in stocks?

HALO is the stock ticker symbol of Halozyme Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Halozyme Therapeutics Inc (HALO)?

As of Wed Apr 24 2024, market cap of Halozyme Therapeutics Inc is 4.96 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HALO stock?

You can check HALO's fair value in chart for subscribers.

What is the fair value of HALO stock?

You can check HALO's fair value in chart for subscribers. The fair value of Halozyme Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Halozyme Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HALO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Halozyme Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether HALO is over valued or under valued. Whether Halozyme Therapeutics Inc is cheap or expensive depends on the assumptions which impact Halozyme Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HALO.

What is Halozyme Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, HALO's PE ratio (Price to Earnings) is 17.62 and Price to Sales (PS) ratio is 5.98. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HALO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Halozyme Therapeutics Inc's stock?

In the past 10 years, Halozyme Therapeutics Inc has provided 0.184 (multiply by 100 for percentage) rate of return.